Neuroptix Corporation, an Acton, MA-based company focused on developing a non-invasive diagnostic platform for the early detection of Alzheimer’s Disease, has closed the first approximately $4m tranche of a Series C funding round.
The investment is being led by Inventages and will be funded in two tranches totalling approximately $8m contingent on the successful completion of undisclosed milestones.
As also stated by Paul Hartung, President and CEO, this financing provides the company with resources to move the Neuroptix SAPPHIRE II System through clinical studies.
The system is a combination product, consisting of an optical measurement device and topical ophthalmic agent being developed to aid in the diagnosis of probable Alzheimer’s Disease.
FinSMEs
11/01/2011